期刊文献+

SIRT1在胃癌组织中表达及对患者预后的影响 被引量:3

Expressions of SIRT1 as prognostic biomarker on resectable gastric cancer patient
下载PDF
导出
摘要 目的:探讨胃癌和癌旁组织中SIRT1的表达及其对患者预后的影响。方法:收集1990年1月至1995年12月142例胃癌单纯手术治疗患者的临床病理资料,术后生存随访资料,将癌组织与相对应癌旁组织制作组织芯片,通过免疫组化的方法,分别获得SIRT1在其中的表达评分。分析SIRT1表达与患者临床病理指标及预后之间的关系。结果:本研究最终获得113例患者的有效信息,SIRT1在113例胃癌组织中的表达显著低于癌旁组织,差异具有统计学意义(P<0.05),癌组织中SIRT1低表达患者癌体浸润深度、淋巴结转移比例、远处转移比例均显著高于高表达患者(P<0.05),pTNM分期晚期比例也高于高表达患者(P<0.05)。胃癌组织中SIRT1表达越高患者预后越好(HR=0.211,95%CI:0.124~0.360,P<0.001)。结论:胃癌组织中SIRT1表达水平与恶性表型呈负性关系,可作为预测手术治疗患者预后的生物标志物。 Objective:To investigate the SIRT1 expressions in gastric cancer tissue and the potential association with clinicopathological characteristics and prognosis of the patients.Methods:The clinicopathological and survival information of the 142 cases who underwent radical gastrectomy at Nantong Cancer Hospital from January 1990 to December 1995,was collected to establish a combined database.The tissue microarray was made from the paraffin embed gastric cancer tissues and corresponding adjacent nontumoral gastric tissues from 142 resectable patients.Expressions of SIRT1 were evaluated by a semi-quantitative immunoreactivity scoring(IRS) procedure.The correlations between the expressions of the SIRT1 and clinicopathological as well as survival characteristics of patients were further analyzed.Results:Expressions of SIRT1 were significantly lower in cancer lesions than in adjacent noncancerous tissues.Low tumoral SIRT1 expression was associated with depth of invasion,presence of lymph node metastasis,high pTNM stage and poor differentiation,respectively.Importantly,reduced SIRT1 expressions in cancerous tissues were significantly correlated with shorter overall survival(OS) in patients(HR = 0.205,95%CI:0.124~0.339,P 〈 0.001).Conclusion: SIRT1 might be a novel biomarker for evaluating progression and prognosis of resectable gastric cancer patients.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第8期1142-1147,共6页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家自然科学基金重点项目资助(30930080)
关键词 SIRT1 胃癌 预后 生物标志物 SIRT1 gastric cancer prognosis biomarker
  • 相关文献

参考文献16

  • 1Jemal A,Thomas A, Murray T,et al. Cancer statistics [J]. CA Cancer J Clin, 2002,52( 1 ) : 23-47.
  • 2Parkin DM, Bray F, Ferlay J,et al. Global cancer statistics [J]. CA Cancer J Clin,2005,55(2) :74-108.
  • 3Roder DM. The epidemiology of gastric cancer [J]. Gastric Cancer, 2002,5 (Suppl 1): 5-11.
  • 4秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 5Deng C. SIRT1,is it a tumor promoter or tumor suppressor[J]. Int J Biol Sci,2009,5(2) : 147-152.
  • 6Remmele W,Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue[J]. Pathology, 1987,8(3) : 138-140.
  • 7Huffman DM,Grizzle WE,Bamman MM,et al. SIRT1 is significantly elevated in mouse and human prostate cancer[J]. Cancer Res, 2007,67(14) :6612-6618.
  • 8Bradbury CA, Khanim FL, Hayden R,et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors [J]. Leukemia,2005,19 (10):1751-1759.
  • 9Stunkel W,Peh BK,Tan Y,et al. Function of the SIRT1 protein deacetylase in cancer [J]. Biotechnol J,2007,2(11):1360-1368.
  • 10Wang R,Sengupta K, Li C,et al. Impaired DNA damage response,genome instability,and tumorigenesis in SIRT1 mutant mice[J]. Cancer Cell,2008,14(4):312-323.

二级参考文献17

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
  • 3Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016.
  • 4Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40.
  • 5Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328.
  • 6Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a.
  • 7Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a.
  • 8Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281.
  • 9Giuliani F,Maiello E,Molica S,et al.Irinotecan (CPT-11)and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients.A phase Ⅱ study of the Gruppo Oncologico dell Italia Meridionale (GOIM)[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4235.
  • 10Shah M A,Ramanathan RK,Ilson D,et al.Final results of a multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2006,24 (18S):Abstract 4020.

共引文献267

同被引文献43

  • 1Conde-Perez A,Larue L.PTEN and melanomagenesis[J].Fu-ture Oncol,2012,8:1109-1120.
  • 2Gupta A,Yang Q,Pandita RK,et al.Cell cycle checkpoint de-fects contribute to genomic instability in PTEN de?cient cellsindependent of DNA DSB repair[J].Cell Cycle,2009,8:2198-2210.
  • 3Gonzalez-Angulo AM,Ferrer-Lozano J,Stemke-Hale K,et al.PI3K pathway mutations and PTEN levels in primary and meta-static breast cancer[J].Mol Cancer ther,2011,10:1093-1101.
  • 4Song MS,Salmena L,Pandolfi PP.The functions and regulationof the PTEN tumour suppressor[J].Nature Reviews MolecularCell Biology,2012,13:283-296.
  • 5Andjelkovica T,Bankovica J,Milosevica Z,et al.Concurrentalteration of p16 and PTEN tumor suppressor genes could be con-sidered as potential molecular marker for specific subgroups ofNSCLC patients[J].Cancer Biomarkers[J].2011,10:277-286.
  • 6Guarente L, Franklin H. Epstein Lecture:Sirtuins, aging, and medicine[J]. N Engl J Med, 2011,364 (23):2235-2344.
  • 7Houtkooper RH, Pirinen E,Auwerx J. Sirtuins as regulators of metabolism and healthspan[J]. Nat Rev Mol Cell Biol, 2012,13 (4):225-238.
  • 8Yang H, Lee SM, Gao B,et al. Historic deaeetylase sirtuin l deacetylates IRF1 protein and programs dendritic cells to control Thl7 protein differ-entiation during autoimmune inflammation[J]. J Biol Chem,2013,288 (52):37256-37266.
  • 9Lin L, Zheng X, Qiu C, et al. SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis[J]. Oncol Rep, 2014,32 (6):2831-2835.
  • 10Davenport AM, Huber FM, Hoelz A. Structural and functional analysis of human SIRT1 [J]. J Mol Biol, 2014,426 (3):526-541.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部